Clinical trials in Nicaragua

Regulatory sources checked November 19, 2026. General sponsor guidance, not legal advice or an approval guarantee.

Nicaragua authorizes human clinical trials of medicines through its National Committee for Health Research (CONIS), under Technical Standard NTON 19001:2022, published in La Gaceta No. 225 on 30 November 2022. CONIS authorizes a medicine trial only after an ethics committee, a scientific research committee, and the national regulatory authority have approved it. That published standard covers medicines. The route for an investigational-device study is confirmed case by case with ANRS and CONIS. A published pathway is not a site-readiness finding or a startup promise.

Request a protocol-specific feasibility assessment

Bring the product description, development stage, preclinical and any foreign-regulator evidence, proposed population, procedures, and follow-up. A Nicaragua commitment should wait on a documented regulatory and operational plan for that protocol. This page does not claim that a study is already running or that a site is ready.

Contact bioaccess®

Key facts

A published CONIS pathway for medicines, and an open question for devices

Medicines. NTON 19001:2022 sets the requirements and procedures for clinical trials of medicines in humans in authorized institutions. It was approved on 6 October 2022 and published in La Gaceta No. 225 on 30 November 2022. MINSA Normativa-166 (Managua, August 2020) carries the same framework on the points cited here. CONIS facilitates and approves health research. A medicine trial may start only when CONIS has authorized it, after approvals from an ethics committee, the scientific research committee, and the national regulatory authority. Text: http://legislacion.asamblea.gob.ni/normaweb.nsf/3133c0d121ea3897062568a1005e0f89/d7588a993b33a293062589100055ba7f?OpenDocument= and https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf.

When CONIS requests it, the national regulatory authority evaluates the investigational product's safety profile and issues a binding technical report within a maximum of 45 business days (Normativa-166, Chapter XI; NTON 19001:2022, same clause). Law 1068, approved 18 March 2021 and published in La Gaceta No. 58 on 24 March 2021, created ANRS (Autoridad Nacional de Regulación Sanitaria) as that authority, attached to the Ministry of Health. The 45 business day limit is one statutory step. It is not an ethics clock or a startup promise. Law 1068: http://legislacion.asamblea.gob.ni/normaweb.nsf/b92aaea87dac762406257265005d21f7/3d4084b456b4529e062586a2006e1f0f?OpenDocument=.

Devices. NTON 24001:2023 sets requirements for sanitary registration of medical devices to be distributed and sold, and it groups devices into four risk classes (I, II, III, and IV). It defines a clinical study and a clinical investigation. It does not set an authorization procedure for an investigational-device study. ANRS has legal competence over medical devices under Law 1068. That competence is not a published device-trial authorization. The route for a device investigation is confirmed case by case with ANRS and CONIS for the protocol in hand. Registration text: https://www.minsa.gob.ni/sites/default/files/publicaciones/NTON%2024001%20Tecnolog%C3%ADa%20de%20la%20salud.%20Dispositivos%20m%C3%A9dicos.%20Requisitos%20para%20el%20Registro%20Sanitario..pdf.

Sponsors and population. A foreign sponsor must have a legal representative in Nicaragua for the duration of the trial (Normativa-166, Chapter VI). ClinicalTrials.gov listed 23 studies with a location in Nicaragua on 19 November 2026, and none had intervention type DEVICE. That count is registry activity, not an enrollment forecast and not a record of work by bioaccess®. Query: https://clinicaltrials.gov/api/v2/studies?query.locn=Nicaragua&countTotal=true.

Direct answers

Who authorizes clinical trials in Nicaragua?

CONIS, the National Committee for Health Research of the Ministry of Health, under NTON 19001:2022 (La Gaceta No. 225, 30 November 2022). It authorizes a medicine trial after approvals from an ethics committee, the scientific research committee, and the national regulatory authority. MINSA Normativa-166 (August 2020) carries the same sequence.

What is the role of ANRS, and what does the 45 business day limit cover?

ANRS is the national health regulation authority created by Law 1068 (2021) and attached to the Ministry of Health. For a medicine trial, the standard has the national regulatory authority evaluate the investigational product's safety profile when CONIS asks, and issue a binding technical report within a maximum of 45 business days (source: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf). That is a statutory limit on one step. It is not an ethics clock or a total approval timeline.

Are device studies regulated separately from device registration?

Registration of devices is separate. NTON 24001:2023 sets sanitary-registration requirements and four risk classes. It does not authorize research. The route for a device investigation is confirmed case by case with ANRS and CONIS. This page does not state that a published device-investigation procedure exists.

Regulatory framework

Confirm the route and the site first

Start with NTON 19001:2022 for a medicine, and confirm with ANRS and CONIS which instrument applies to the product in front of you. The research center must be authorized by CONIS to run clinical trials, and the host institution must authorize the study. A device investigation is confirmed case by case with ANRS and CONIS. NTON 24001:2023 is a registration standard, not a study permit. Each product and site needs its own assessment.

Nicaragua device registration

Get ethics and scientific approval

Sponsors need approval from an ethics committee authorized by CONIS and, for a medicine trial, from the scientific research committee, before CONIS authorizes the study (Normativa-166, Chapters VI and VII; NTON 19001:2022). Medicine trials must also meet the Declaration of Helsinki, the Belmont Report, and internationally accepted good-clinical-practice standards (Normativa-166, general provisions). The consent form is filed in Spanish and in its original language. Translation alone does not prove that a participant understood the study. We did not find a public roster of every committee CONIS has authorized. Confirm the committee's current authorization before planning.

File the CONIS dossier

The application to CONIS includes the signed application form, the research-center registration, the host institution's authorization, the protocol and consent form, the ethics approval letter, the investigator's brochure, a detailed budget, the sponsor's insurance policy, the list of investigational products and supplies, investigator CVs, and proof of payment of the procedural fee the standard requires. This page does not quote that fee. Phase I to III studies have added requirements, such as prior animal toxicity data and a suitably equipped facility (Normativa-166, Chapter VII). Information is filed in the original language with a Spanish translation. An official or legal document is filed as an original or a legalized copy, in Spanish or with an official translation, and a foreign official document is legalized under the national rule. An official document with no stated validity is treated as valid for two years from its issue date for the filing (NTON 19001:2022, general provisions 8 to 10).

Plan insurance, import, and activation

The sponsor must hold insurance for trial participants, or commit by notarial declaration to cover trial-related harm, and the policy copy goes in the file. The standard calls for national coverage, and a foreign insurer needs a legal representative in Nicaragua (Normativa-166, Chapters V and VI). Import of investigational products follows the national regulatory authority's rules, and the sponsor keeps an import register. Biological products need apostilled or consularized batch documents. A GMP certificate for a third-country manufacturer must be legalized. Approval, import clearance, and site activation are distinct steps.

Plan safety reporting and post-trial care

Investigators report serious adverse events to the sponsor, the ethics committee, CONIS, and the national regulatory authority within 24 hours of learning of them, unless the protocol states that immediate notice is not required for specified events (Normativa-166, Chapter XII). The sponsor must keep the trial documentation and data for at least 10 years after the trial ends (source: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf). The sponsor must also ensure post-trial access to beneficial interventions when no adequate alternative exists, until the product is commercially available, and describe this in the consent form.

Keep commercial registration off the trial file

A device sanitary registration under NTON 24001:2023 and a trial authorization are different files. bioaccess® can process a manufacturer-funded registration as a scoped engagement. The registration holder is the product owner, who authorizes its local distributor. A registration does not replace study authorization or ethics review, and it does not authorize a device investigation. The device-investigation route is confirmed case by case with ANRS and CONIS.

MINSA device registration

Key advantages

Nicaragua compared with the United States and the EU

Topic Nicaragua United States EU
Trial frameworkNTON 19001:2022 (medicines); device route confirmed case by case21 CFR 812 and IRB review (devices)EU CTR or MDR, plus national ethics
Authorizing bodyCONIS, after ethics, scientific, and ANRS approvals (medicines)FDA / IRBNational competent authorities and ethics committees
Registry activity (ClinicalTrials.gov, 19 Nov 2026)23 studies; 0 deviceVery largeLarge
FDA use of the dataConditional under 21 CFR 812.28Domestic fileConditional, with justification
Cost versus a U.S. programScoped to the protocolBaselineScoped to the protocol

Regulatory details reflect NTON 19001:2022 and Normativa-166 as read on 19 November 2026 (source: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf). The 45 business day period is the national regulatory authority's technical-report limit when CONIS requests it, not an ethics clock or a startup promise. The registry count is ClinicalTrials.gov on 19 November 2026 (source: https://clinicaltrials.gov/api/v2/studies?query.locn=Nicaragua&countTotal=true). Eligibility under 21 CFR 812.28 is not FDA clearance or approval. NTON 24001:2023 is device registration only. A device investigation is confirmed case by case with ANRS and CONIS.

Read the pathway, then scope the protocol

Use this page to see the published sequence for a medicine: product and site eligibility, ethics and scientific approval, the CONIS dossier, and insurance, import, and activation. Then ask for a feasibility assessment of the protocol in front of you. Nicaragua has its own authority and its own files. A plan for another country does not relabel this one.

Sponsors should also have counsel review U.S. sanctions exposure under OFAC's Nicaragua-related program for counterparties, sites, and payments before committing (https://ofac.treasury.gov/sanctions-programs-and-country-information/nicaragua-related-sanctions).

See the first-in-human CRO overview.

Next to Nicaragua: clinical trials in Guatemala.

Next to Nicaragua: clinical trials in Honduras.

Commercial file: MINSA device registration.

After the trial: LATAM post-trial access.

Frequently asked questions

Who regulates clinical trials in Nicaragua?

CONIS, the National Committee for Health Research of the Ministry of Health, authorizes medicine trials under NTON 19001:2022 after approvals from an ethics committee, the scientific research committee, and the national regulatory authority (ANRS under Law 1068).

What is the role of ANRS?

Law 1068 (2021) created ANRS as the national health regulation authority attached to the Ministry of Health, with competence that includes medicines and medical devices. For a medicine trial, Normativa-166 Chapter XI gives the national regulatory authority up to 45 business days for a binding technical report on the product's safety profile when CONIS requests it (source: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf). That is not an ethics clock or a startup promise. Law 1068 does not itself publish a device-investigation authorization.

Does the standard cover medical devices?

NTON 19001:2022 and Normativa-166 cover medicines. NTON 24001:2023 covers device registration, including four risk classes, and it is not a study permit. The route for a device investigation is confirmed case by case with ANRS and CONIS.

Do foreign sponsors need a local representative?

Yes. A foreign sponsor must have a legal representative in Nicaragua for the duration of the trial (Normativa-166, Chapter VI).

Is insurance required?

Yes. The sponsor must hold a policy for participants, or commit by notarial declaration to cover trial-related harm, and file the policy copy with the application. The standard calls for national coverage. This page does not quote a premium.

What language must documents be in?

Information is filed in the original language with a Spanish translation. Consent forms are filed in Spanish and the original language. Official or legal documents are filed in Spanish or with an official translation, and foreign official documents must be legalized (NTON 19001:2022, general provisions 8 to 10).

How long does approval take?

No total timeline is published. Normativa-166 Chapter XI gives the national regulatory authority up to 45 business days for its binding safety report when CONIS requests it (source: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf). That limit is not an ethics clock or a startup promise. Ethics, scientific review, and CONIS decision times are not published in the sources checked on 19 November 2026.

Must the investigational product already be approved elsewhere?

For medicines, an application can be filed only if the product meets one of the conditions in NTON 19001:2022 and Normativa-166, Chapter XI. One is authorization for human research from a recognized international regulator. Another is a public-health priority with Phase I and II results from the country of origin. Confirm which condition the product meets.

Is post-trial access required?

Yes. The sponsor must ensure access to beneficial interventions after the trial until the product is commercially available, where no adequate alternative exists, and describe this in the consent form (Normativa-166, Chapter VI).

Does the FDA accept clinical data from Nicaragua?

Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when that rule's conditions are met, including ethics-committee oversight and informed consent (https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-812/subpart-C/section-812.28). Eligibility is not clearance or approval. A Nicaragua device investigation still has to be confirmed case by case with ANRS and CONIS.

Does this page promise a cost or speed advantage?

No. Cost follows product complexity, sites, participants, follow-up, imaging, import, and insurance. No savings percentage and no total approval timeline are stated here.

Is bioaccess® already running trials in Nicaragua?

This page does not say that. Request a feasibility assessment for the protocol you actually have, and confirm a documented plan before you commit the country.

Sources

Last reviewed: November 2026

Related pages

All countries we serve · Contact bioaccess® · First-in-Human CRO